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SUMMARY
Objective: To investigate the biological origin of injectable unfractioned heparin avail-
able in Brazilian market by discussing the impact of the profile of commercial prod-
ucts and the changes in heparin monograph on the drug safety.  Methods: The Anvisa 
database for the Registered Products of Pharmaceutical Companies and the Dictionary 
of Pharmaceutical Specialties (DEF 2008/2009) were searched. A survey with industries 
having an active permission for marketing the drug in Brazil was conducted. Results: 
Five companies were granted a permission to market unfractioned heparin in Brazil. 
Three of them are porcine in origin and two of them are bovine in origin, with only one 
explicitly showing this information in the package insert. The effectiveness and safety 
of heparin studied in non-Brazilian populations may not represent the Brazilian reality, 
since most countries no longer produce bovine heparin. The currently marketed heparin 
has approximately 10% less anticoagulant activity than that previously produced and this 
change may have clinical implications. Conclusions: Evidence about the lack of dose 
interchangeability between bovine and porcine heparins and the unique safety profile of 
these drugs indicates the need to follow the treatment and the patients’ response. Events 
threatening the patient’s safety must be reported to the pharmacovigilance system in 
each particular country.
Keywords: Heparin; anticoagulants, product surveillance; drug monitoring; drug toxicity.
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INTRODUCTION
Heparin is a natural agent with an anticoagulant action. 
The drugs commercially available are isolated and ex-
tracted from porcine intestinal mucosa and bovine pul-
monary tissue. Heparin isolation and extraction process 
leads to partial degradation of glycosaminoglycan chains 
that make it up1, producing a drug composed of molecular 
fragments with heterogeneous molecular weights, ranging 
from 3,000 to 30,0002, and known as unfractioned hepa-
rin (UFH), standard heparin or simply heparin. Heparin 
pharmacokinetic and pharmacodynamic properties also 
show great heterogeneity due to different anticoagulant 
potencies of action presented by fractions with distinc-
tive molecular weights and also due to heparin binding to 
plasma cells and proteins.
Another type of commercially available heparin, the 
low molecular weight heparin (LMWH), is made up of 
molecular fragments with average molecular weight 5,000 
and it is obtained by acid depolymerization of standard 
heparin3. As different depolymerization methods are avail-
able, there are different low molecular weight heparins2. 
LMWH preparations have more predictable pharmacoki-
netic and pharmacodynamic properties, thus being more 
convenient than UFH when used in different clinical set-
tings2. Actually, in several countries, LMWHs are replac-
ing UFH. In Brazil, however, several clinical interventions 
are still UFH-dependent4. Furthermore, in Brazil, the de-
livery of heparin from both available animal sources is still 
remaining, whereas in the United States and in Europe 
bovine UFH is no longer produced because of the bovine 
spongiform encephalopathy epidemics5,6.
In 2008, a contamination in batches of UFH marketed 
by Baxter Healthcare, a major producer of the drug in sev-
eral countries, brought out a serious world crisis in hepa-
rin market6. The contaminant identified, the oversulfated 
chondroitin sulfate, is a substance similar to heparin and 
its administration brought on reactions characterized by 
hypotension, nausea and respiratory distress, occurring 
within 30 minutes of exposure6. These reactions were asso-
ciated with over 200 deaths in several countries7. In Brazil, 
the international crisis was added to the unexplained mar-
ket withdrawal of the intravenous unfractioned heparin by 
Roche (Liquemine) in 20074.
The crisis caused by the heparin contamination culmi-
nated with several changes in clinical and drug produc-
tion actions. In a global level, the heparin monograph was 
revised by the United States Pharmacopoeia (USP) and by 
the World Health Organization aiming to introduce qual-
ity tests able to detect the oversulfated chondroitin sulfate 
which were not previously contemplated7,8. In Brazil, hep-
arin shortage stimulated a market restructuring, with the 
introduction of new suppliers and consequently new raw 
material sources for the product4,9,10. All these changes im-
pact heparin pharmacovigilance, introducing new safety 
issues regarding therapy vigilance in UFH anticoagula-
tion. In view of these issues, the objective of this study was 
to investigate the biological origin of injectable heparin 
preparations which are available in Brazilian market, dis-
cussing the impact of the profile of commercial products 
and the changes in heparin monograph on the drug phar-
macovigilance.
METHODS
In order to determine the biological origin or UFH inject-
able preparations in Brazil, the Anvisa database for Regis-
tered Products of Pharmaceutical Companies of the Nation-
al Health Surveillance Agency (Anvisa)11 was searched to 
identify pharmaceutical companies with a permission 
to market the drug in the country. In addition, the Dic-
tionary of Pharmaceutical Specialties (DEF 2008/2009) 
was also consulted. The companies identified with an ac-
tive permission for the drug trade were initially contacted 
by telephone via Consumer Attendance Service (SAC) and 
via e-mail later. The contact with the companies followed a 
standardized form with the purpose of addressing the fol-
lowing topics: kinds of heparin currently produced by the 
company if any; commercial name and formulation of 
the product; main commercial destination of the drug (hos-
pital or drugstores), and biological origin of the heparin.
The survey was conducted between August 19 and 
September 28, 2010 by the team of the Drug Study Cen-
ter of the Universidade Federal de Minas Gerais, Pharmacy 
School (Cemed – UFMG).
RESULTS
Nine trademarks filed with Anvisa were identified and 
they concerned eight pharmaceutical companies manu-
facturing heparin as an injectable formulation. One of the 
companies could not be located by the available references 
and was excluded from the query. Out of the eight trade-
marks whose producer company could be contacted, one 
(Heparin™), is no longer produced, having been replaced 
by another product (Hemofol™) by the same producer 
laboratory. Among the remaining trademarks, two have 
a registration expired with Anvisa and they are in a pro-
cess of permission renewal (manufacturer’s information) 
and three companies have an active permission to market 
heparin in Brazil.
Among the products with an active license or in a re-
newal process, three consist of an injectable formulation 
for a subcutaneous route administration (3/5), one con-
sists of a formulation for intravenous administration (1/5) 
and one is a formulation intended for either subcutaneous 
or intravenous administration (1/5).
Regarding the biological origin of the drugs, three (60%) 
are porcine in origin and two (40%) are bovine in origin, 
with only one having this information explained in the 
package insert. Out of the five pharmaceutical companies 
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Table 1 – Unfractioned heparins marketed in Brazil according to the commercial name, raw material biological origin, 
pharmaceutical formulations and main product commercial destination
Commercial name Biological origin Pharmaceutical formulations Main commercial destination
Actparin Bovine
5,000 UI/mL (IV)
5,000 UI/0.25 mL (SC)
Hospitals (IV and SC) 
Drugstores (IV)
Hemofol Porcine
5,000 UI/0.25 mL (SC)
5,000 UI/mL (IV)
Hospitals
Hepamax-s Porcine 5,000 UI/mL (IV e SC) Hospitals
Heptar Bovine 5,000 UI/mL (IV) Hospitals
Parinex Porcine
5,000 UI/mL (IV)
5,000 UI/0.25 mL (SC)
Hospitals
IV, intravenous route; SC, subcutaneous route
producing heparin in Brazil, four market their products 
only to hospitals and one to both hospitals and drugstores.
The commercial names of the drugs identified, as well as 
the raw material biological origin, the available pharmaceu-
tical formulations and the main commercial destination of 
the products are summarized in Table1.
DISCUSSION
The pharmacovigilance, the Phase IV in drug clinical stud-
ies, comprises activities related to detection, evaluation, 
understanding, and prevention of adverse events or any 
issues related to the drugs with the purpose of identifying 
risks and preventing damage to patients12. Various aspects 
of the drug post-marketing period are of interest to phar-
macovigilance, including continued eff cacy review, adverse 
reactions, adverse events from quality deviation, off-label 
use, drug interactions, therapeutic ineffectiveness events, 
poisonings related to drugs and also potential or actual 
medication errors13,14.
Although UFH has been the major tool in managing 
thromboembolic conditions for over 50 years15, the drug has 
aroused great interest to the pharmacovigilance system as a 
function of recent commercial and clinical circumstances, 
demonstrating a necessary warning regarding its use.
UFH biological origin is a seldom explored factor in the 
guidelines of the drug dose and dose regimen. However, the 
drug animal source changes its effectiveness and safety pro-
file16,17. Actually, bovine heparin and porcine heparin are not 
equivalent drugs16. Bovine heparin has a higher sulfatation 
degree of its compounds and this determines distinct effects 
from porcine heparin regarding coagulation, thrombosis, 
and bleeding. Bovine heparin also differs in its aff nity for 
protamine, a substance used in the drug anticoagulant ef-
fect inhibition. All of these issues can show the lack of dose 
interchangeability between bovine and porcine heparins, 
thus stressing the need of treatment monitoring. Thus, the 
UFH biological origin may affect effectiveness and safety as-
pects of the therapy upon using the drug. The issue assumes 
a particular relevance when we observe this information is 
commonly missing in drug labels and drugs with different 
biological origins are simultaneously and interchangeably 
marketed in Brazil.
LMWHs, in turn, are not affected by the drug biologi-
cal origin aspects because bovine heparin is not used in 
their production due to possible viral contaminants, such as 
those in bovine spongiform encephalopathy15.
The recent crisis in heparin market gave rise to another 
issue with a global impact, stressing the warning regarding 
UFH use: changes in the drug monograph. All products 
marketed in Brazil and in the world must be submitted to 
the new recommendations established in UFH monograph 
by the World Health Organization and the United States 
Pharmacopoeia aiming to assure the safety and quality of 
active pharmaceutical ingredients7,8,18. The amendments 
foresee the introduction of additional tests which must be 
used by producers to identify contaminants and the imple-
mentation of a new potency assay. The new recommended 
potency test, the anti-factor IIa chromogenic assay, offers 
higher additional specificity and safety against potential 
adulterants mimicking heparin activity. In parallel with the 
new test introduction, a new potency reference standard 
was also defined8. In addition, the heparin potency unit 
used by the United States Pharmacopoeia was harmonized 
with the International Unit (IU) used by the World Health 
Organization.
Although the changes in heparin monograph have con-
tributed to a safer and higher quality product, the question 
remaining is the clinical significance of the drug potency 
change. Studies conducted by the agency regulating drugs 
in the United States, the Food and Drug Administration 
(FDA), demonstrated heparin produced in accordance with 
the new specifications in the USP monograph was approxi-
mately 10% less active as an anticoagulant than the heparin 
previously produced, which stresses potency changes may 
have clinical implications in certain settings, such as the in 
bolus intravenous administration19. Yet USP, responsible for 
the new monograph, does not anticipate the potency change 
shows any clinical relevance20.
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Regardless the diverging views about the clinical im-
pact of the new heparin potency, the need of a careful clin-
ical follow-up of the drug effect and the patients’ response 
to the “new” medication7,8,19 is a consensus. Any suspicious 
changed response must be evaluated and spread to the 
community through a report to the responsible depart-
ment19,20.
Among the adverse events of interest to pharmaco-
vigilance, adverse drug reactions should be highlighted, as 
they are on the base of great disasters related to medica-
tion use in populations and because about half of drugs 
are known to induce adverse reactions detected only in the 
post-marketing phase (pharmacovigilance)13. Heparin-
induced adverse reactions include hemorrhage, anaphy-
lactic reaction, liver enzyme elevation, osteoporosis (over 
a long time of use) and heparin-induced thrombocytope-
nia (known as HIT)21. Heparin-induced hemorrhage and 
thrombocytopenia are pointed out for their frequency 
and severity.
Bleeding associated with heparin use may occur in any 
site and they are incident in frequencies between 5% and 
10%21. Actually, hemorrhage is a known risk with hepa-
rins, being an extended therapeutic action of the agent. 
Bovine heparin use increases this hemorrhage risk because 
the doses required to induce bleeding seem to be lower 
than those with porcine heparin16. Heparin-induced hem-
orrhage adverse reactions must therefore be reported to 
the pharmacovigilance system, always including the drug 
biological origin into the event report. This information 
allows the appropriate understanding development about 
this subject and the risk epidemiologic profile establish-
ment of heparins marketed in Brazil.
Heparin-induced thrombocytopenia is a frequent and 
potentially fatal immunodependent adverse reaction22-24. 
A major consequence is the increased paradoxical risk 
of thromboembolic complications. This reaction under-
standing is still improving. Its incidence is known to be 
variable, depending on the heparin type used, whether 
UFH or LMWH, as well as the patient population ex-
posed17. The subgroup with the highest risk includes pa-
tients using UFH postoperatively (1% to 5%). The reaction 
incidence is variable according to the UHF biological ori-
gin, with bovine heparin being more immunogenic than 
porcine heparin17.
In Brazil, heparin-induced thrombocytopenia inci-
dence remains unknown, as well as its clinical implication 
severity. This is worrisome, considering the differences 
of UFH marketed in Brazil: while most countries do not 
produce bovine heparin, 40% of products delivered to our 
market are this kind of heparin. Thus, knowledge based on 
data about this reaction produced in markets and popula-
tions in other countries may not represent our reality. Giv-
en this issue relevance, which is demonstrated by several 
studies in other countries, notably in North Hemisphere 
countries, as well as the frequency and potentiality for the 
development of major clinical events resulting from hep-
arin-induced thrombocytopenia, this is a worrying gap in 
our pharmacovigilance system.
The lack of knowledge about the HIT epidemiologic 
profile in Brazil can further be associated with an impor-
tant economic impact. Every 15 new cases recognized per 
year costs the institution between 700,000 and 1.8 million 
dollars25. On the other hand, the reaction clinical non-rec-
ognition may result in improper treatments, increased life 
or amputation risk and a further increase in financial and 
life cost.
In Brazil, Anvisa has been expanding its activities in 
pharmacovigilance and currently the sector has an im-
proved and e cient online reporting system26. Health 
practitioners, users and the pharmaceutical industry are 
stimulated to feed the system and collaborate with safe and 
effective use of drugs marketed in the country.
CONCLUSION
The evidence about the lack of dose interchangeability 
between bovine and porcine origin heparins, the unique 
safety profile between these agents and the permanence of 
heparins produced from different animal sources in Bra-
zilian market indicate the need of treatment and patient 
response follow-up. Heparin effectiveness and safety stud-
ied in non-Brazilian populations may not represent Bra-
zilian reality, since most countries do not produce bovine 
heparin and the heparin currently marketed is approxi-
mately 10% less active as an anticoagulant than that previ-
ously produced, this change can have clinical implications. 
The need of clinical studies to test the safety and e ca-
cy of heparin formulations used in Brazil is highlighted. 
The pharmacovigilance system must be communicated 
about events threatening the patient’s safety.
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